Merck to acquire Caraway Therapeutics
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
The newly established business will be looking for high-quality, mid- to late-stage assets, clinically focused on the United States market
This innovative solution comes as an answer to the industry-wide challenges of availability, cost, and dependencies linked to custom and proprietary hardware components
Distributes Ayushman cards to several beneficiaries
Decision on EU marketing authorisation expected for momelotinib by early 2024
Emphasizes the need for a collective effort on bolstering resilience across economies, societies, healthcare systems, education systems and infrastructure
The product will be manufactured at Lupin’s Nagpur facility in India
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Subscribe To Our Newsletter & Stay Updated